December 02, 2024
Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance
November 20, 2024
Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program
October 23, 2024
Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon
October 16, 2024
Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss
October 01, 2024
Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss
September 05, 2024
Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity
September 03, 2024
Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program
September 03, 2024
Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to its Board of Directors
June 20, 2024
Allurion Reports Lean Mass Gains with 14% Weight Loss
June 11, 2024
Allurion Presents at ASMBS Annual Meeting
June 05, 2024
Allurion Appoints Ojas A. Buch as COO
May 30, 2024
Allurion Expands AI Weight Loss Coach for GLP-1 Support
May 15, 2024
Allurion Presents at European Obesity Congress
May 02, 2024
Allurion Presents at IFSO-Europe 2024
April 03, 2024
Allurion Expands Virtual Care Suite to the United States
January 29, 2024
Brendan Gibbons Named Chief Legal Officer
January 23, 2024
Somerset NHS Treats First Patients with Allurion Balloon
January 16, 2024
Expanding Our Digital Platform with New Partnerships
January 11, 2024
Allurion Publishes Study on Improved Obesity Co-Morbidities
January 05, 2024
New Research Highlights GLP-1s' Impact
January 02, 2024
Allurion’s Digital Platform Expands with New Partnership
October 11, 2023
Allurion completes AUDACITY trial enrolment.
October 04, 2023
Allurion to Present Five Abstracts at Obesity Week 2023
September 18, 2023
Allurion at Oxford University World Congress
August 29, 2023
Allurion Presents Coach Iris: 24/7 AI Weight Loss Guide.
August 28, 2023
Allurion Presents Nine Abstracts at IFSO
August 01, 2023
Allurion Debuts as a Publicly Traded Company on the NYSE
July 25, 2023
Allurion Updates Board of Directors and Leadership
June 28, 2023
Allurion Showcases 20% Weight Reduction Data at 2023 ASMBS
June 22, 2023
Allurion Partners with Medtronic for AI Weight Loss Access.
May 30, 2023
Allurion to Participate in the Jefferies Healthcare Conference
May 16, 2023
Allurion & GLP-1 Study Showcased at European Obesity Congress
May 15, 2023
Allurion Shares Results from Remote Weight Loss Study
April 12, 2023
Allurion Unveils Premium Care Suite & 'My Daily Action' Bundle
April 05, 2023
Allurion Appoints Regina Barzilay, Ph.D. to Advisory Board
March 01, 2023
Allurion Named Champion Partner' of World Obesity Federation.
February 09, 2023
Allurion to Become Publicly Listed
December 15, 2022
Allurion's Training Gains SCOPE Accreditation
November 16, 2022
Allurion added to Deloitte List of Fastest Growing Companies
October 27, 2022
Allurion Receives Approval to Launch in Brazil
October 19, 2022
Allurion launches in India
October 19, 2022
Allurion Unveils Major Update to the Virtual Care Suite
October 19, 2022
Allurion Crosses 100,000 Patients Treated
October 04, 2022
Allurion Balloon Results In Significant Weight Loss